Results 191 to 200 of about 113,181 (243)

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection—General and Special Populations

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 945-954, April 2026.
Current first‐line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Lung‐Yi Mak, Tsung‐Hui Hu, Desmond Y. H. Yap   +2 more
wiley   +1 more source

HBV genotype distribution and S gene mutations in HIV-HBV co-infected patients: insights from North India. [PDF]

Front Cell Infect Microbiol
Sami H, Asaad M, Husaini SHM, Khan PA, Raza A, Fatima N, Khan HM.   +6 more
europepmc   +1 more source

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 955-966, April 2026.
In the phase I/IIa GOING trial, an add‐on strategy with regorafenib followed by nivolumab showed a manageable safety profile and meaningful clinical activity in second‐line hepatocellular carcinoma, with a median overall survival of 25 months and 45% three‐year survival in sorafenib‐experienced patients.
Marco Sanduzzi‐Zamparelli, Ana Matilla, José Luis Lledo, Sergio Muñoz‐Martínez, María Varela, Mercedes Iñarrairaegui, Christie Perelló, Beatriz Mínguez, Neus Llarch, Laura Márquez, Antonio Guerrero, Gemma Iserte, Andrés Castaño‐García, Laura Carrión, Marta Fortuny, Jordi Rimola, Ángeles García‐Criado, Gema Domenech, Ferran Torres, José Rios‐Guillermo, Loreto Boix, Esther Samper, Àngels Kateb, Jordi Bruix, Maria Reig   +24 more
wiley   +1 more source

Assessment of self-reported prevalence, vaccination status, knowledge and behavioral determinants of hepatitis B and D in Pakistan: a cross-sectional study. [PDF]

Front Microbiol
Rahman SU, Gao Y, Noor F, Ullah M, Rahman HU, Qadeer A, Ullah T, Chi X, Niu J, Hamid S, Zhang Z.   +10 more
europepmc   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

European Journal of Haematology, Volume 116, Issue 4, Page 336-349, April 2026.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard‐Rohner   +3 more
wiley   +1 more source

New Insights into the Role of NF-κB in Hepatitis B Virus Infection. [PDF]

Int J Biol Sci
Halemubieke S, Liu X, Yan Y, Ji H, Sun H, Ma J, Chang L, Wang L.   +7 more
europepmc   +1 more source

The Impact of Hepatitis C and Socio‐Demographic Variables on Health‐Related Quality of Life in Pakistan: Cross‐Sectional Study

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Approximately 8.8 million people are living with chronic hepatitis C virus (HCV) in Pakistan. We assessed factors related to health‐related quality of life (HRQoL) among the general population screened for HCV and calculated the national burden in quality‐adjusted life years (QALYs).
Siwaporn Niyomsri, Aaron G. Lim, Ambreen Arif, Muhammad Asim, Auj Chaudhry, Naheed Choudhry, Aliya Hasnain, Polychronis Kemos, Chris Metcalfe, Asad Choudhry, Saeed Sadiq Hamid, Saad Niaz, Huma Qureshi, Graham R. Foster, Peter Vickerman, Josephine G. Walker, HepFreePak team, Aqsa Ramzan, Atif Saghir, Ejaz Alam, Ghayas Hai, Mohd Saadullah, Muhammad Nabeel Shafqat, Muhammad Sufyan Tahir, Taha Khan   +24 more
wiley   +1 more source

Gustave Roussy Immune Score Predicts Outcomes in Hepatocellular Carcinoma Treated with TACE and Immunotherapy. [PDF]

J Hepatocell Carcinoma
Qin L, Xu XY, Yang H, Li W, Zhang S, Shen J, Zhu X.   +6 more
europepmc   +1 more source

Prevalence and Factors Associated With Hepatitis C in Danish Prisons, 2022–2024: A Multicentre Cross‐Sectional Study

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Prisons offer a critical opportunity for hepatitis C virus (HCV) elimination, yet current data from Danish correctional facilities are sparse. We conducted a cross‐sectional study in 16 prisons across Eastern Denmark between October 2022 and August 2024, enrolling 651 incarcerated individuals.
Jonas Demant, Jacob Søholm, Jeffrey V. Lazarus, Louise Krohn‐Dehli, Christina Egelund, Søren Madsen, Toke Barfod, Cécile Kremer, Stephen Strunge Nilsson, Ditte Andersen Skovdal, Nina Weis   +10 more
wiley   +1 more source